Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSGO-OV-UMB1; ENGOT-OV30 umbrella trial in relapsed ovarian cancer
2017-002805-36Phase 2Completed
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- Aug 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer and Malignant ovarian neoplasm (OC) comparing Cohort A: MEDI9447 + Durvalumab with Standard-of-care comparator (2 arms). Primary endpoint: Disease control rate at 16 weeks. Started Aug 2017; status: completed.
02
Drugs
oleclumabdurvalumab
03
Conditions
ovarian cancerMalignant ovarian neoplasm (OC)
Beyond the preview
Go deeper on 2017-002805-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002805-36.